Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 12 de 12
1.
Bioorg Med Chem Lett ; 26(11): 2670-5, 2016 06 01.
Article En | MEDLINE | ID: mdl-27107947

Prostaglandin E receptor subtype 3 (EP3) antagonism may treat a variety of symptoms from inflammation to cardiovascular and metabolic diseases. Previously, most EP3 antagonists were large acidic ligands that mimic the substrate, prostaglandin E2 (PGE2). This manuscript describes the optimization of a neutral small molecule amide series with improved lipophilic efficiency (LipE) also known as lipophilic ligand efficiency (LLE) ((a) Nat. Rev. Drug Disc.2007, 6, 881; (b) Annu. Rep. Med. Chem.2010, 45, 380).


Amides/pharmacology , Receptors, Prostaglandin E, EP3 Subtype/antagonists & inhibitors , Amides/chemical synthesis , Amides/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Structure-Activity Relationship
2.
J Med Chem ; 59(3): 1165-75, 2016 Feb 11.
Article En | MEDLINE | ID: mdl-26734723

Inhibition of the sodium-coupled citrate transporter (NaCT or SLC13A5) has been proposed as a new therapeutic approach for prevention and treatment of metabolic diseases. In a previous report, we discovered dicarboxylate 1a (PF-06649298) which inhibits the transport of citrate in in vitro and in vivo settings via a specific interaction with NaCT. Herein, we report the optimization of this series leading to 4a (PF-06761281), a more potent inhibitor with suitable in vivo pharmacokinetic profile for assessment of in vivo pharmacodynamics. Compound 4a was used to demonstrate dose-dependent inhibition of radioactive [(14)C]citrate uptake in liver and kidney in vivo, resulting in modest reductions in plasma glucose concentrations.


Citrates/metabolism , Malates/chemistry , Malates/pharmacology , Phenylbutyrates/chemistry , Phenylbutyrates/pharmacology , Pyridines/chemistry , Pyridines/pharmacology , Symporters/antagonists & inhibitors , Animals , Biological Transport/drug effects , Blood Glucose/metabolism , Citrates/pharmacokinetics , Dose-Response Relationship, Drug , HEK293 Cells , Hepatocytes/drug effects , Humans , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/metabolism , Malates/administration & dosage , Male , Mice , Mice, Inbred C57BL , Mice, Obese , Molecular Structure , Phenylbutyrates/administration & dosage , Pyridines/administration & dosage , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Symporters/metabolism
3.
J Med Chem ; 58(18): 7164-72, 2015 Sep 24.
Article En | MEDLINE | ID: mdl-26258602

Inhibition of triacylglycerol (TAG) biosynthetic enzymes has been suggested as a promising strategy to treat insulin resistance, diabetes, dyslipidemia, and hepatic steatosis. Monoacylglycerol acyltransferase 3 (MGAT3) is an integral membrane enzyme that catalyzes the acylation of both monoacylglycerol (MAG) and diacylglycerol (DAG) to generate DAG and TAG, respectively. Herein, we report the discovery and characterization of the first selective small molecule inhibitors of MGAT3. Isoindoline-5-sulfonamide (6f, PF-06471553) selectively inhibits MGAT3 with high in vitro potency and cell efficacy. Because the gene encoding MGAT3 (MOGAT3) is found only in higher mammals and humans, but not in rodents, a transgenic mouse model expressing the complete human MOGAT3 was used to characterize the effects of 6f in vivo. In the presence of a combination of diacylglycerol acyltransferases 1 and 2 (DGAT1 and DGAT2) inhibitors, an oral administration of 6f exhibited inhibition of the incorporation of deuterium-labeled glycerol into TAG in this mouse model. The availability of a potent and selective chemical tool and a humanized mouse model described in this report should facilitate further dissection of the physiological function of MGAT3 and its role in lipid homeostasis.


Acyltransferases/antagonists & inhibitors , Isoindoles/chemistry , Sulfonamides/chemistry , Acyltransferases/genetics , Animals , Cells, Cultured , Diacylglycerol O-Acyltransferase/antagonists & inhibitors , Dogs , Humans , Isoindoles/pharmacokinetics , Isoindoles/pharmacology , Mice, Transgenic , Molecular Docking Simulation , Structure-Activity Relationship , Sulfonamides/pharmacokinetics , Sulfonamides/pharmacology , Triglycerides/biosynthesis
4.
Org Lett ; 16(1): 154-7, 2014 Jan 03.
Article En | MEDLINE | ID: mdl-24308287

Organozinc reagents react with the SO2 surrogate DABSO, and the resulting zinc sulfinate salts are alkylated in situ to afford sulfones. This transformation has a broad scope and is compatible with a wide range of structural motifs of medicinal chemistry relevance including nitrile, secondary carbamates, and nitrogen-containing heterocycles.


Dapsone/chemistry , Hydrocarbons, Halogenated/chemistry , Organometallic Compounds/chemistry , Sulfones/chemical synthesis , Zinc/chemistry , Molecular Structure , Sulfones/chemistry
5.
Bioorg Med Chem Lett ; 23(24): 6588-92, 2013 Dec 15.
Article En | MEDLINE | ID: mdl-24239482

Glucokinase (hexokinase IV) continues to be a compelling target for the treatment of type 2 diabetes given the wealth of supporting human genetics data and numerous reports of robust clinical glucose lowering in patients treated with small molecule allosteric activators. Recent work has demonstrated the ability of hepatoselective activators to deliver glucose lowering efficacy with minimal risk of hypoglycemia. While orally administered agents require a considerable degree of passive permeability to promote suitable exposures, there is no such restriction on intravenously delivered drugs. Therefore, minimization of membrane diffusion in the context of an intravenously agent should ensure optimal hepatic targeting and therapeutic index. This work details the identification a hepatoselective GKA exhibiting the aforementioned properties.


Enzyme Activators/chemistry , Glucokinase/chemistry , Hypoglycemic Agents/chemistry , Allosteric Regulation , Animals , Cells, Cultured , Diabetes Mellitus, Type 2/drug therapy , Drug Evaluation, Preclinical , Enzyme Activators/metabolism , Enzyme Activators/therapeutic use , Glucokinase/metabolism , Hepatocytes/cytology , Hepatocytes/enzymology , Humans , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/therapeutic use , Imidazoles/chemistry , Injections, Intravenous , Niacin/analogs & derivatives , Niacin/chemistry , Rats , Tissue Distribution
6.
J Med Chem ; 56(17): 7110-9, 2013 Sep 12.
Article En | MEDLINE | ID: mdl-23981033

Acetyl-CoA carboxylase (ACC) catalyzes the rate-determining step in de novo lipogenesis and plays a crucial role in the regulation of fatty acid oxidation. Alterations in lipid metabolism are believed to contribute to insulin resistance; thus inhibition of ACC offers a promising option for intervention in type 2 diabetes mellitus. Herein we disclose a series of ACC inhibitors based on a spirocyclic pyrazololactam core. The lactam series has improved chemical and metabolic stability relative to our previously reported pyrazoloketone series, while retaining potent inhibition of ACC1 and ACC2. Optimization of the pyrazole and amide substituents led to quinoline amide 21, which was advanced to preclinical development.


Acetyl-CoA Carboxylase/antagonists & inhibitors , Lactams/pharmacology , Animals , Area Under Curve , Lactams/chemistry , Magnetic Resonance Spectroscopy
7.
J Med Chem ; 56(1): 301-19, 2013 Jan 10.
Article En | MEDLINE | ID: mdl-23234271

A series of GPR119 agonists based on a 2,6-diazatricyclo[3.3.1.1∼3,7∼]decane ring system is described. Also provided is a detailed account of the development of a multigram scale synthesis of the diazatricyclic ring system, which was achieved using a Hofmann-Löffler-Freytag reaction as the key step. The basis for the use of this complex framework lies in an attempt to constrain one end of the molecule in the "agonist conformation" as was previously described for 3-oxa-7-aza-bicyclo[3.3.1]nonanes. Optimization of carbamate analogues of the diazatricylic compounds led to the identification of 32i as a potent agonist of the GPR119 receptor with low unbound human liver microsomal clearance. The use of an agonist response weighted ligand lipophilic efficiency (LLE) termed AgLLE is discussed along with the issues of applying efficiency measures to agonist programs. Ultimately, solubility limited absorption and poor exposure reduced further interest in these molecules.


Aza Compounds/chemical synthesis , Bridged-Ring Compounds/chemical synthesis , Cyclodecanes/chemical synthesis , Receptors, G-Protein-Coupled/agonists , Animals , Aza Compounds/chemistry , Aza Compounds/pharmacology , Biological Availability , Bridged-Ring Compounds/chemistry , Bridged-Ring Compounds/pharmacology , Crystallography, X-Ray , Cyclodecanes/chemistry , Cyclodecanes/pharmacology , Dogs , Drug Design , Humans , Male , Microsomes, Liver/metabolism , Molecular Structure , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Pyrimidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/chemistry , Solubility , Stereoisomerism , Structure-Activity Relationship
8.
Org Lett ; 11(4): 1007-10, 2009 Feb 19.
Article En | MEDLINE | ID: mdl-19178159

A mild method to access a variety of substituted indole derivatives has been developed. The strategy relies on the generation of highly reactive indolyne intermediates, which function as electrophilic indole surrogates.


Combinatorial Chemistry Techniques , Indoles/chemistry , Indoles/chemical synthesis , Catalysis , Models, Molecular , Molecular Structure
9.
J Am Chem Soc ; 130(39): 13177-81, 2008 Oct 01.
Article En | MEDLINE | ID: mdl-18767844

The kendomycin skeleton was prepared by a highly convergent strategy in which the benzofuran fragment and the acyclic iodide fragment were prepared by standard methods and joined using a Suzuki coupling. The distinctive reaction in our approach was an intramolecular Prins cyclization that assembles the macrocyclic ring in good yield. Modeling studies demonstrate that the acyclic chain is predisposed for macrocycle formation. Ultimately, the product was correlated with one of Lee's advanced intermediates for a formal total synthesis of kendomycin.


Rifabutin/analogs & derivatives , Cyclization , Macrocyclic Compounds/chemical synthesis , Rifabutin/chemical synthesis , Stereoisomerism
12.
J Am Chem Soc ; 124(19): 5528-41, 2002 May 15.
Article En | MEDLINE | ID: mdl-11996596

The interaction of vapor-deposited Al atoms with self-assembled monolayers (SAMs) of HS-(CH(2))(16)-X (X = -OH and -OCH(3)) chemisorbed at polycrystalline Au[111] surfaces was studied using time-of-flight secondary-ion mass spectrometry, X-ray photoelectron spectroscopy, and infrared reflectance spectroscopy. Whereas quantum chemical theory calculations show that Al insertion into the C-C, C-H, C-O, and O-H bonds is favorable energetically, it is observed that deposited Al inserts only with the OH SAM to form an -O-Al-H product. This reaction appears to cease prior to complete -OH consumption, and is followed by formation of a few overlayers of a nonmetallic type of phase and finally deposition of a metallic film. In contrast, for the OCH(3) SAM, the deposited Al atoms partition along two parallel paths: nucleation and growth of an overlayer metal film, and penetration through the OCH(3) SAM to the monolayer/Au interface region. By considering a previous observation that a CH(3) terminal group favors penetration as the dominant initial process, and using theory calculations of Al-molecule interaction energies, we suggest that the competition between the penetration and overlayer film nucleation channels is regulated by small differences in the Al-SAM terminal group interaction energies. These results demonstrate the highly subtle effects of surface structure and composition on the nucleation and growth of metal films on organic surfaces and point to a new perspective on organometallic and metal-solvent interactions.


Alcohols/chemistry , Aluminum/chemistry , Ethers/chemistry , Gases , Hydrocarbons/chemistry , Mass Spectrometry/methods , Spectrophotometry, Infrared , Sulfhydryl Compounds/chemistry , Surface Properties
...